TMCnet - World's Largest Communications and Technology Community



Research and Markets: OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018
[August 29, 2014]

Research and Markets: OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018" report to their offering.

The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL (News - Alert)), currently revolves around multiple rounds of Rituxan-based chemotherapy.

Although patients can achieve durable remissions to induction therapy, those patients who relapse after primary treatment have poor progosis and high unmet needs. Several promising pipeline agents are set to have a dramatic impact on treatment of these relapsed/refractory patients over the forecast period: Pharmacyclics'/Janssen's Imbruvica, which was approved for relapsed/refractory MCL patients in November 2013, Gilead's Zydelig, which was approved for relapsed/refractory FL patients in July 2014, and Roche's Gazyva, which will launch in 2015.

Key Questions Answered:

  • How will the launch of Imbruvica and Zydelig impact the treatment landscape of relapsed/refractory MCL and FL patients?
  • How will the launch of Gazyva and the subcutaneous formulation of MabThera help Roche protect their hematology franchise from biosimilar rituximab competition in the 5EU?
  • The new agents will launch first in one B-cell indication before seeking label expansion into broader NHL patient populations. How will companies expand their hematology candidates beyond their initial approvals?
  • Pharmacyclics has set a high pricing bar with a high ACOT for Imbruvica. How will this pricing strategy affect pricing of other pipeline agents, and will this be a barrier to entry in cost-conscious EU markets?
  • The new agents address significant unmet needs in the relapsed/refractory NHL population. What remaining opportunity will remain after their launch?

Key Topics Covered:

1 List of Tables

2 Introduction

3 Disease Overview

4 Disease Management

5 Epidemiology

6 Current Treatment Options

7 Unmet Needs Assessment and Opportunity Analysis

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy